Investors


Investor Relations


Interim Summary

TurnoverQ1 2021

45 (34)

MSEK

EBITDAQ1 2021

-9 (2)

MSEK

Christer Ahlberg
President and CEO

CEO Comments

Sedana Medical operates according to a clear strategy to develop inhaled sedation into a global standard therapy in intensive care. The first quarter of the year was notable for preparations ahead of our European launch of Sedaconda (isoflurane) during the second half of the year and ahead of our forthcoming expansion in the United States. Day-to-day operations and our sales continued to be dominated by the COVID-19 pandemic.

ICU sedation is precisely the treatment that severely ill COVID-19 patients very often need, and demand for AnaConDa and accessories was strong during the third wave of the pandemic that hit many countries during the first quarter. Sales in the quarter were SEK 45 million, up 40 percent on the previous year, at constant exchange rates. The trend in sales continued to be highly positive as a result of COVID-19. We are, however, seeing a further increase in freight costs compared with previously, as a result of the pandemic, which has a negative impact on our gross profit. Adjusted for the increased freight costs our underlying gross margin is now slightly higher than in previous quarters. In terms of sales, we now recognise Germany, our distribution markets and other direct sales markets, which show that demand rose sharply in our distribution countries, focused on Latin America. Germany was hit by a third wave during the quarter, contributing to an increase mainly at the end of the quarter. Since the end of the quarter, we have also succeeded in having our quality system approved under MDR 2017/745, which is a decisive milestone for the future.

Our strategic plan to achieve our vision of making inhaled sedation a new global standard therapy in intensive care is based on four steps: 1) Establish AnaConDa in as many markets as possible. 2) Apply for marketing authorisation for Sedaconda, initially in the EU and later in other markets. 3) Secure strong medical evidence. 4) Establish the therapy in guidelines as a first-line alternative. We made progress in all these steps during the quarter.

With regard to establishing AnaConDa in as many markets as possible, during the quarter we strengthened our presence in the Middle East and South America, where we are working closely with our distributors. In South America, demand additionally increased sharply as a result of the pandemic, and we launched the therapy at many new clinics via our distributor. By establishing AnaConDa in as many markets as possible, we are building experience at the clinics ahead of market approval for Sedaconda. In that way, we are building on a solid foundation for continued expansion.

With regard to the second step in our strategy, having the pharmaceutical product Sedaconda and inhaled sedation therapy approved, it was very pleasing to submit applications for marketing authorisation for Sedaconda in the United Kingdom and Switzerland during the quarter. As a result, the treatment will move from being off-label to fully approved, and we will be able to sell the whole therapy, that is to say both the medical device AnaConDa with accessories and the pharmaceutical product Sedaconda. We submitted an EU application at the end of last year, and if everything goes well we anticipate approval in 15 EU countries during the second half of 2021. We anticipate being able to launch during the first half of 2022 in the United Kingdom and during 2022 in Switzerland.

Now that we are approaching commercialisation in Europe, our work has been concentrated on launch activities. A key factor in successful commercialisation is acceptance by payers in healthcare systems, and during the quarter we worked intensively to establish good contacts and have devoted a large amount of time to preparing price, procurement and reimbursement processes in various countries.

The preparations ahead of our American registration were intensive during the quarter. We are working on several parallel processes ahead of the IND (Investigational New Drug) application which is required to enable us to initiate two pivotal phase 3 studies. Among other things, we have initiated processes to recruit our own staff in the United States, to take part in the study work there, and during the quarter we continued to work in particular on completing the tox studies and the human factors validations to enable us to submit the IND application.

Some processes have, however, been delayed by the pandemic, in particular the interaction with the FDA, which has significantly prolonged response times. As a consequence, we no longer anticipate being able to obtain IND approval after the summer but rather during the autumn, and we therefore anticipate including the first patient in the study concerned at the end of Q1 or the beginning of Q2 2022. We are doing what we can to speed up the processes while maintaining quality and to prepare the clinics to be involved in the studies in the best possible way, for efficient patient recruitment when it gets underway.

With regard to the third step in our strategy, securing medical evidence with the help of more studies showing that inhaled sedation is a better and more cost-effective treatment than the current standard therapy, it is very pleasing that during the quarter we were able to announce that the first patient had been included in our paediatric study IsoCOMFORT (SED002). This study is conducted to investigate if inhaled sedation with Sedaconda delivered via AnaConDa is a safe and more effective method of sedation than intravenously administered midazolam for children below 18 years of age. The study is expected to be completed during the second half of 2022 and is intended to lead to an approved paediatric indication for inhaled sedation.

IsoCOMFORT (SED002) is our first own ‘superiority’ study. This means a study performed to show that inhaled sedation with AnaConDa has characteristics superior to intravenous standard sedation. The investigator-initiated studies we support – INASED, SESAR and ISCA – are all superiority studies performed to demonstrate significant benefits, for example with regard to wake-up times, shorter time to extubation, fewer side effects such as delirium, higher proportion of spontaneous breathing in patients, better oxygen uptake, shorter ICU treatment times etc. As a result, the treatment will gain ground and be included in national and international recommendations, as well as gradually taking the position of a new standard therapy throughout the world.

Overall, we can look back on another intensive quarter. This is my twentieth quarter as CEO of Sedana Medical, and these are probably my last CEO Comments as the company’s CEO. It has been highly enjoyable and exciting years, and it has been an honour to build up Sedana Medical along with all the incredibly professional employees. In view of how well Sedana Medical has developed, the time feels right to hand over the baton to a new CEO.

The company has developed superbly well over those years, with a multiple increase in sales, while we have marketing authorisation within reach later this year and establishment of a presence in the United States in years to come. Sedana Medical today has a very solid foundation on which to successfully develop inhaled sedation into a global standard.

Christer Ahlberg, President and CEO

 Read the report in its entirety here.

Calendar
Dates for upcoming information

Date Event
19 August, 2021 Q2 interim report 2021
4 November, 2021 Q3 interim report 2021

Annual & Interim Reports

2016
Annual Reports Interim Reports
2016  Sedana Medical AB (publ)
Annual Report 2016 (in Swedish)
N/A N/A

Click on the + sign to expand reports on desired year, then click on a report to open it.
You need a pdf reader to view the files.

Content

Annual General Meeting 2021

Downloadable files:

Annual General Meeting 2020

Downloadable files:

Annual General Meeting 2019

Downloadable files:

Annual General Meeting 2018

Downloadable files:

  Notice of Annual General Meeting 2018
  Nomination Committee’s proposal
  Power of Attorney form
  Minutes from the Annual General Meeting 2018


Corporate Governance

Corporate governance includes information about our Board of Directors, the management team, guidelines for remuneration to the senior management, our auditors, general meetings and our articles of association.

Board of Directors

The registered office of the company is situated in the municipality of Danderyd. The Board of Directors shall consist of not less than three (3) and not more than six (6) members.

Thomas Eklund Chairman
of the Board
  • Born: 1967
  • Nationality: Swedish
  • Position: Board member and Chairman of Sedana Medical since 2014.
  • Education and professional experience: Thomas holds an MBA from the Stockholm School of Economics. 25 years of experience from leading positions in banking, life science and healthcare. CEO, Investor Growth Capital (renamed as Patricia Industries) during 2002–2012, a private equity company owned by Investor AB with a focus on long-term investments in technology, industrial and healthcare. Former board member in life science companies, e.g. Swedish Orphan International AB (chairman) and Carmel Pharma AB.
  • Other current engagements: Board member in Biotage AB, Bio-Works Technologies AB, Bio-Works Sweden AB, Boule Diagnostics AB, Excillum Aktiebolag, Immedica Pharma Holding AB, Mabtech Group Holding AB, Mabtech Holding AB, Surgical Science Sweden AB, Swedencare AB (publ) and board member in affiliates to these companies and smaller family companies.
  • Shareholding in Sedana Medical: 1,666,464 shares via Tedsalus AB.
    Independent in relation to the Company and its management and in relation to major shareholders.
Claus BjerreMember &
vice chairman
of the Board
  • Born: 1971
  • Nationality: Danish
  • Position: Member and vice chairman of Sedana Medical since 2021.
  • Education and professional experience: Claus holds an M.Sc. from the Copenhagen Business School and an MBA in Strategy and Finance from the UCLA Anderson School of Management. He served as CEO of Atos Medical from early 2014 through 2018. Atos Medical was sold by EQT to PAI Partners during his tenure in 2016. From 2006 to 2014, Claus held numerous senior leadership positions with Coloplast A/S, a Danish global consumable medtech company, most recently as President, North America, Japan, and Australia. Before joining Coloplast, Claus spent 10 years within corporate strategy, mergers and acquisitions, and private equity across industries working for McKinsey & Company, Nordic Capital, and Mattel.
  • Other current engagements: Claus is currently ordinary member of the board of directors and vice chairman of the board of Ellab, owned by EQT, and senior advisor at KKR & Co, Inc.
  • Shareholding in Sedana Medical: 0 shares.
    Independent of major shareholders, not independent of the Company and the Executive Management.
Bengt Julander Member
of the Board
  • Born: 1953
  • Nationality: Swedish
  • Position: Member of the Board of Sedana Medical since 2011.
  • Education and professional experience: Bengt is a qualified pharmacist, M.Sc. from Uppsala University. Bengt has more than 30 years of experience in the life science industry. Owner and Chairman in Linc AB, with investments in the pharmaceutical and medtech industry.
  • Other current engagements: Chairman in Linc AB and Knil AB. Board member in Animal Probiotics Sweden AB, Cronhamn Invest AB, Livland Skog AB, Medivir Aktiebolag, nWise AB, Part Production Sweden AB, Reison Medical AB, Stille AB and Swevet Holding AB. Board member and deputy board member in affiliates to these companies and smaller family companies.
  • Shareholding in Sedana Medical: 7,598,804 shares via Linc AB.
    Independent in relation to the Company and its management but not in relation to major shareholders.
Ola Magnusson
Member
of the Board
  • Born: 1948
  • Nationality: Swedish
  • Position: Member of the Board of Sedana Medical since 2005. Formerly CEO of Sedana Medical (2005 – 2011).
  • Education and professional experience: Ola hold an upper secondary school qualification in engineering specializing in chemistry from Gothenburg Technical Upper Secondary School. Ola has more than 25 years of experience in the pharmaceutical industry mainly within marketing, sales and different management positions including 4 years in the US for Pharmacia in the 80ies and 90ies. Ola also has more than 20 years experience in the medical device industry as CEO for Louis Gibeck AB where he was responsible for the listing on the OTC exchange in Stockholm and as Managing Director EMEA, Hudson RCI AB after its acquisition of Louis Gibeck AB. Ola was the founder of Sedana Medical 2005 and acted as CEO up to 2011.
  • Other current engagements: Chairman in Eataway AB. Board member in TransCutan AB and board member in smaller family companies.
  • Shareholding in Sedana Medical: 4,629,728 shares privately and via Magiola Consulting AB.
    Independent in relation to the Company and its management and in relation to major shareholders.
Eva Walde Member
of the Board
  • Born: 1963
  • Nationality: Swedish
  • Position: Member of the Board of Sedana Medical since 2018.
  • Education and professional experience: Eva has a BSc from the School of Economics in Gothenburg, Sweden. Over 20 years of experience in the pharmaceutical and medical technology industry, mainly in marketing and sales as well as management. Formerly VP Commercial Operations, International Region at Phadia / ThermoFisher Scientific as well Strategic Affairs Director at Johnson & Johnson Nordic AB, Medical Device and Strategic Development Manager at Pfizer AB.
  • Other current engagements: Vice President Marketing Director at Olink Proteomics AB, board member at Senzime AB, CEO and Chairman of the board in the own company Movits Consulting AB and deputy board member in Finnson & Partners AB.
  • Shareholding in Sedana Medical: 12,800 shares.
    Independent in relation to the Company and its management and in relation to major shareholders.
Christoffer Rosenblad Member
of the Board
  • Born: 1975
  • Nationality: Swedish
  • Position: Member of the Board of Sedana Medical since 2020.
  • Education and professional experience: Christoffer has a Master of Science degree from Chalmers University of Technology and a degree in economics from the School of Business and Economics at the University of Gothenburg. During 2012-2020 he was CFO for XVIVO Perfusion AB. During the years 2015–2017, he led XVIVO’s North American operations and resided in the United States. From 2001 to 2012, he has had leading positions in finance and strategic management at Novartis and LG Electronics.
  • Other current engagements: COO (since 2020) and Vice President (since 2017) at XVIVO Perfusion AB.
  • Shareholding in Sedana Medical: no shares.
    Independent in relation to the Company and its management and in relation to major shareholders.

Management team

Jens Lindberg
Interim CEO & Vice President Commercial Operations
  • Born: 1971
  • Nationality: Swedish
  • Position: Vice President Commercial Operations since April 2020 and Interim CEO from June 1st, 2021, employed since 2020.
  • Education and professional experience: B.S. Business Administration & 25 years of experience from local & global commercial roles in AstraZeneca.
  • Other current engagements:
  • Shareholding in Sedana Medical: 0 shares. 12,000 warrants in program 2020/2023
    representing 12,000 shares.
Susanne Andersson
CFO
  • Born: 1971
  • Nationality: Swedish
  • Position: Chief Financial Officer since January 2021.
  • Education and professional experience: Bachelor of Business Administration from College of Charleston, S.C. USA. CFO at Pricer, CFO & Head of Communications at ChromoGenics, VP Head of Investor Relations at PostNord, CFO at Nordic Mines and 15+ years of international experience of various finance and management roles within Ericsson and the telecom industry.
  • Other current engagements:
  • Shareholding in Sedana Medical: no shares.
Sylvia Buddenbaum Eriksson
HR director
  • Born: 1968
  • Nationality: Swedish
  • Position: HR director, Consultant since August 2020.
  • Education and professional experience: B.Sc. Business and Economics, Stockholm University. Consultant own business since February 2019. Previously i.a. HR director GroupM, HR director Lidl Sweden, HR & Communication Apoteksgruppen AB/Apoteket omstrukturering AB, HR director Unilever Nordic and different roles within finance.
  • Other current engagements:
  • Shareholding in Sedana Medical: no shares, Related parties 472 shares.
Robert vom Dorp
Vice President Business Development
  • Born: 1970
  • Nationality: German
  • Position: Vice President Business Development since April 2020, employed
    since 2005.
  • Education and professional experience: Robert holds an MBA in economics from the University of Applied Sciences at Hochschule Koblenz. Has also studied industrial organisation. Experience in sales in the medtech industry since 2001 as account manager within anaesthesia, ventilation and intensive care at Hudson RCI and Teleflex Medical. Sales manager at Sedana Medical with responsibilities for marketing, sales, strategy and operations in Germany, Austria and Switzerland.
  • Other current engagements:
  • Shareholding in Sedana Medical: 400,000 shares.
Peter Fröberg
Chief Technology Officer
  • Born: 1971
  • Nationality: Swedish
  • Position: Chief Technology Officer, Consultant since November 2020.
  • Education and professional experience: MSc from the Royal Institute of Technology in Stockholm. More than 20 years’ experience of product and business development, as product manager at Elekta Instrument AB and as a consultant within Life Science.
  • Other current engagements:
  • Shareholding in Sedana Medical: no shares.
Stefan Krisch
Supply Chain & Manufacturing Director
  • Born: 1974
  • Nationality: Swedish
  • Position: Supply Chain and Manufacturing Director since March 2021.
  • Education and professional experience: : Stefan holds a Master of Science degree in Mechanical Engineering from KTH Stockholm, Sweden, and TUD Darmstadt, Germany. In addition he studied business administration and management at Stockholm Business School, Stockholm University. Stefan has some 20 years of experience in leading positions in various industries. Mainly within manufacturing, logistics, and business development. Previously CEO of Svensk Dos AB, CEO of Dipylon Medical AB and Production Manager at AB Gustavsberg. Founder of Eker Bicycles AB and Eker Production Ltd., Uganda.
  • Other current engagements: Chairman of the Board Eker Bicycles AB and Eker Production Ltd., Uganda. Owner K-Consulting (sole proprietor).
  • Shareholding in Sedana Medical: 5,600 shares, 25,200 warrants.
Peter Sackey
CMO
  • Born: 1971
  • Nationality: Swedish
  • Position: Chief Medical Officer of Sedana Medical since January 2018, employed since 2018.
  • Education and professional experience: Peter received his doctor´s degree from Karolinska Institutet in 1997. He has worked for twenty years at the Department of Perioperative Medicine and Intensive Care, Karolinska University Hospital and is Board-certified in Anesthesiology (DESA) and Intensive Care (EDIC). He completed his PhD thesis entitled “Isoflurane sedation in Intensive Care Unit patients” at Karolinska Institutet in 2006. He is an Associate professor at Karolinska Institutet, has supervised several PhD students and has active ICU-related research.
  • Previous positions: Senior Consultant, Head of Neurocritical Care, Department of Perioperative Medicine and Intensive Care, Karolinska University Hospital in Stockholm.
  • Other current engagements: Associate professor, Department of Physiology and Pharmacology, Karolinska Institutet.
  • Shareholding in Sedana Medical: 252,568 shares and 105,172 warrants in program 2019/2022 representing 105,172 shares.
Jessica Westfal
Vice President Regulatory Affairs & QA
  • Born: 1974
  • Nationality: Swedish
  • Position: Vice President Regulatory Affairs and QA since May 2020, employed since 2020.
  • Education and professional experience: Jessica holds a MSc in Analytical Chemistry at
    Umeå University. She is a former employee at Unimedic AB (between 2006-2020) as Head of Quality and Product Development, and before that at AstraZeneca (between 1998-2006).
  • Other current engagements:
  • Shareholding in Sedana Medical: no shares. 4,000 warrants in program 2020/2023
    representing 4,000 shares.

Guidelines for remuneration to senior management

The main principle is that remuneration and other employment conditions for members of senior manage¬ment shall be based on market terms and be competitive in order to ensure that the group can attract and retain competent senior managers at a reasonable cost for the company.

The total remuneration for senior management shall consist of fixed salary, variable remuneration, pension and other benefits.

The Board fee is decided by the Annual General Meeting. In so far as board members elected by the Annual General Meeting are performing work that stretches beyond the tasks of the Board of Directors, it shall be possible to pay them for such work. Such remuneration shall be market-based and shall be approved by the Board of Directors.

The remuneration to the Board of Sedana Medical is determined at the Annual General Meeting following proposals from the Nomination Committee.

Audit Committee

During 2020 an audit committee was established. On behalf of the Board, the Audit Committee monitors and reviews the following:

  • The scope and correctness of the financial statements
  • Compliance with legal and regulatory requirements
  • Internal control over financial reporting
  • Risk management
  • The Annual Report and interim reports
  • Audits and audit fees

Members of the Audit Committee
The Audit Committee consists of three Board members as appointed by the Board. The current members are:
Christoffer Rosenblad (Chairman of the Committee)
Thomas Eklund
Bengt Julander

Auditor

Öhrlings PricewaterhouseCoopers AB was elected as auditors at the Annual General Meeting in May 2021 for the period leading up to the Annual General Meeting 2022. The principal responsible is authorized public accountant Leonard Daun.

Fees for auditing in Sedana Medical are determined at the AGM following proposals from the Nomination Committee.

General Meeting

The General Meeting of shareholders is the highest decision-making entity in Sedana Medical AB. At the General Meeting, all shareholders are invited to exercise their rights according to their respective shareholdings.

Shareholders wishing to participate in General Meetings must be listed as a shareholder in a printout or other presentation of the entire share register reflecting the circumstances five weekdays before the General Meeting and notify the company no later than the date specified in the notice of the General Meeting. A shareholder may be accompanied by advisers at a General Meeting only if he or she notifies the company of the number of advisers in accordance with the procedure prescribed for in respect of notice of attendance to be made by a shareholder.

ARTICLES OF ASSOCIATION OF SEDANA MEDICAL AB (PUBL)

Reg. no. 556670-2519

Adopted at the annual general meeting held on 10 May 2021

§ 1 Name of the company
The name of the company is Sedana Medical AB (publ).

§ 2 Registered office of the board of directors
The registered office of the company shall be situated in the municipality of Danderyd.

§ 3 Object of the company’s activities
The object of the company’s activities is to develop, manufacture and market pharmaceuticals and medical- technical products,
and other activities compatible therewith.

§ 4 Share capital
The share capital shall be not less than SEK 800,000 and not more than SEK 3,200,000.

§ 5 Number of shares
The number of shares shall be not less than 32,000,000 and not more than 128,000,000.

§ 6 Board of Directors
The board of directors shall consist of not less than three (3) and not more than six (6) members. The members are to be elected annually at the annual general meeting until the end of the next annual general meeting.

§ 7 Auditors
The company shall have a minimum of one (1) and a maximum of two (2) auditors, with a maximum of two (2) deputy auditors. A registered accounting firm may also be appointed as auditor.

§ 8 Place of General Meetings
Any general meeting in the Company shall be held in Danderyd or Stockholm.

§ 9 Notice of General Meeting
Notices of general meetings shall be made by announcement in the Swedish Official Gazette (Sw. Post- och Inrikes Tidningar) and by making the notice available on the company’s website. At the same time as notice is given it shall be announced in Dagens industri that a notice has been made.

Shareholders wishing to participate at a general meeting shall notify the company no later than the date specified in the notice of the general meeting. Such date may not be a Sunday, other public holiday, Saturday, Midsummer’s Eve, Christmas Eve or New Year’s Eve and may not occur earlier than the fifth weekday before the general meeting. A shareholder may be accompanied by advisors at a general meeting only if he or she notifies the company of the number of advisors in accordance with the procedure prescribed for in respect of notice of attendance to be made by a shareholder.

§ 10 Annual General Meeting
The following matters shall be addressed at the annual general meeting:
1. Election of chairman of the meeting

2. Preparation and approval of the voting register

3. Election of one or two persons to attest the minutes

4. Determination of whether the meeting has been duly convened

5. Approval of the agenda

6. Presentation of the annual report and auditor’s report and, where applicable, the consolidated financial statements and the auditor’s report on the group

7. Resolutions regarding:

(a) adoption of the balance sheet and income statement and, where applicable, the consolidated balance sheet and the consolidated income statement

(b) allocation of the company’s profit or loss according to the adopted balance sheet

(c) discharge from liability for board members and the managing director

8. Determination of fees to be paid to the board of directors and the auditors

9. Determination of the number of board members and, where applicable, deputy members, and the number of auditors and, where applicable, deputy auditors

10. Election of the board of directors and auditors

11. Any other business incumbent on the meeting according to the Swedish Companies Act or the articles of association

§ 11 Financial year
The company’s financial year shall be 1 January – 31 December.

§ 12 CSD clause
The shares of the company shall be registered in a CSD register in accordance with the Central Securities Depositaries and Financial Instruments Accounts Act (Sw. lagen (1998:1479) om värdepapperscentraler och kontoföring av finansiella instrument).

 Click here to download the Articles of Association.

Ownership

Below is Sedana Medical’s ownership structure.

NameNum. of sharesCapitalVotesVerified       
Handelsbanken Funds 8,495,052 9.22% 9.22% 2021-06-30
Swedbank Robur Funds 8,314,933 9.02% 9.02% 2021-06-30
Linc AB (Bengt Julander) 7,598,804 8.24% 8.24% 2021-06-30
Anders Walldov 7,100,000 7.70% 7.70% 2021-06-30
Ola Magnusson 4,613,728 5.00% 5.00% 2021-05-26
Sten Gibeck 4,279,776 4.64% 4.64% 2021-06-30
Öhman Funds 3,902,588 4.23% 4.23% 2021-06-30
Berenberg Funds 2,162,344 2.35% 2.35% 2020-12-31
Avanza Pension 1,947,394 2.11% 2.11% 2021-06-30
Third Swedish National Pension Fund 1,900,000 2.06% 2.06% 2021-06-30
Total 1050,314,61954.58%54.58%
Others41,872,34145.42%45.42%
Total number of owners 6,333 2021-06-30
Total number of shares 92,186,960 2021-06-30

Source: Modular Finance

Warrant programmes

Sedana Medical has outstanding warrant programmes with a total maximum dilution of 547 272 shares.
Warrant program 2019/2022, total maximum dilution of 356 340 shares,
exercisable 1 July to 30 November 2022 at a strike price of 35,60 SEK per share.
Warrant program 2020/2023, total maximum dilution of 42 480 shares,
exercisable 1 July to 30 November 2023 at a subscription price of SEK 83,70 per share.
Warrant program 2020/2024, total maximum dilution of 148 452 shares,
exercisable 1 February to 31 May 2024 at a subscription price of SEK 123,90 per share.

Presentations

Date Description Material
May 6, 2021 Sedana Medical – webcast Q1 2021 report.
To participate, please dial: +46 8 505 566 426 93
For additional log in information:
https://financialhearings.com/event/13793
https://tv.streamfabriken.com/sedana-medical-q1-2021
 More info
Feb 25, 2021 Sedana Medical – webcast Q4 report.  More info
Nov 26, 2020 Sedana attending Redeye Life Science Day 2020.  Play Video
Nov 17-19, 2020 Sedana attending 11th Annual Jefferies Global Healthcare Conference.  More info
Nov 5, 2020 – 14:00 Sedana Medical – webcast Q3 report.  More info
Sept 9, 2020 Sedana attending Carnegie Virtual Nordic Small Mid Cap Seminar.  View Program
Sept 2-3, 2020 Sedana attending Pareto Securities’ 11th Annual Healthcare Conference.  More info
Sept 1, 2020 Sedana attending Danske Bank Small & Mid Cap Seminar.  Play Video
July 10, 2020 Presentation of the positive top line result in the pivotal IsoConDa study.  Play Live Stream
May 19, 2020 CEO presentation in connection with AGM 2020-05-19.  Play Video
May 7, 2020 Presentation of the interim report for the first quarter 2020.  Play Video
April 8, 2020 Sedana Medical’s CEO on prioritizing in the Corona crisis.  Play Video
November 27, 2019 VATOR SECURITIES UNICORN SUMMIT 2019.  Play Video
September, 2019 Sedana Medical – Management Presentation September 2019.  View Presentation
June 10, 2019 Redeye Growth Day 2019.  Play Video
May 8, 2019 Presentation of the interim report for the first quarter 2019.  Play Video
March 14, 2019 Stockholm Corporate Finance Life Science Seminar.  Play Video
March 8, 2019 IsoConDa phase III pivotal study, interim analysis report, 8 March 10:30.  Play Video
September 6, 2018 Pareto Securities’ 9th Health Care seminar in Stockholm.  Play Video
April 27, 2018 Event at ProHearings (English).  Play Video
March 7, 2018 Sitdown at Erik Penser 2018 (Swedish).  Play Video
March 6, 2018 Stockholm Corporate Finance Life Science Seminar (Swedish).  Play Video
November 24, 2017 Redeye seminar (Swedish).  Play Video
June 29, 2017 Trading Direkt Interview with CEO Christer Ahlberg (Swedish).  Play Video

Shares

Stock Graph

Share
ISIN-code
Share
Shortname
Current
Share Price
SE0015988373 SEDANA  Click here!
The LEI code is: 549300FQ3NJRI56LCX32
Certified Adviser: Erik Penser Bank – Tel: +46 (0)8-463 80 00 – Apelbergsgatan 27, Box 7405, 103 91 Stockholm, Sweden
Analyst(s) covering Sedana Medical: Peter Östling, Pareto Securities

IPO

 Sedana Medical Investor Relation

 

Address:
Sedana Medical AB (publ)
Vendevägen 89
SE-182 32 Danderyd
Sweden
Phone: +46 (0)8-124 05 200
Investor relation: ir@sedanamedical.com